Cargando…

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma

PURPOSE: Raltitrexed shows therapeutic effects and safety in many types of malignant tumors. However, reports of the clinical outcomes of raltitrexed-based transarterial chemoembolization (TACE) or drug-eluting beads TACE (DEB-TACE) in the treatment of hepatocellular carcinoma (HCC) are rare. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Yonghua, Wang, Yang, Zhang, Wenguang, Lu, Huibin, Ren, Jianzhuang, Han, Xinwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945722/ https://www.ncbi.nlm.nih.gov/pubmed/36814327 http://dx.doi.org/10.1186/s40644-023-00534-1

Ejemplares similares

Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
por: Bi, Yonghua, et al.
Publicado: (2022)

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis
por: Bi, Yonghua, et al.
Publicado: (2022)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma
por: Ghosh, Abheek, et al.
Publicado: (2022)

Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients
por: Zhu, Dedong, et al.
Publicado: (2019)

Evaluation of the Safety and Efficacy of Conventional Transarterial Chemoembolization (cTACE) and Drug-Eluting Bead (DEB)-TACE in the Management of Unresectable Hepatocellular Carcinoma: A Systematic Review
por: Ayyub, Javaria, et al.
Publicado: (2023)

Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients
por: Li, Ningjie, et al.
Publicado: (2022)

Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)
por: Wiggermann, Philipp, et al.
Publicado: (2011)

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads
por: Bi, Yonghua, et al.
Publicado: (2022)

A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma
por: Shi, Xiaonan, et al.
Publicado: (2023)

Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE
por: Chai, Bin, et al.
Publicado: (2022)

Clinical outcomes of doxorubicin-eluting CalliSpheres beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma
por: Bi, Yonghua, et al.
Publicado: (2021)

The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
por: Bi, Yonghua, et al.
Publicado: (2022)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
por: Fan, Wenzhe, et al.
Publicado: (2022)

Neuroendocrine Tumor Treated with Arterial Chemoembolization Using DEB-TACE
por: Suzuki, Ko, et al.
Publicado: (2019)

Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
por: Shao, Wenbo, et al.
Publicado: (2019)

Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study
por: Xiang, Hua, et al.
Publicado: (2019)

Quantitative analysis with multiphase contrast-enhanced computed tomography to evaluate residual tumor activity of hepatocellular carcinoma after DEB-TACE
por: Hu, Wenchao, et al.
Publicado: (2023)

Portal Vein Damage after DEB-TACE and Lipiodol-TACE: Based on Evaluation by Computed Tomography during Arterial Portography
por: Tamura, Masashi, et al.
Publicado: (2021)

Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
por: Pitton, Michael B., et al.
Publicado: (2014)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

DEB TACE for Intermediate and advanced HCC – Initial Experience in a Brazilian Cancer Center
por: Luz, Jose Hugo Mendes, et al.
Publicado: (2017)

Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis
por: Bargellini, Irene, et al.
Publicado: (2021)

Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Li, Baojian
Publicado: (2022)

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Liu, Baojiang, et al.
Publicado: (2019)

Hepatic arterial infusion of oxaliplatin plus raltitrexed in unresectable hepatocellular carcinoma with or without portal vein tumour thrombosis
por: Chen, Shiguang, et al.
Publicado: (2022)

TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma
por: Huang, Dexiao, et al.
Publicado: (2017)

Retracted: Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study
por: Healthcare Engineering, Journal of
Publicado: (2023)

Performance and Safety of a Reflux-Control Microcatheter Used to Perform DEB-TACE with LUMI(TM) Beads in HCC Patients: Preliminary Experience
por: Angileri, Salvatore Alessio, et al.
Publicado: (2023)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
por: Lu, Haohao, et al.
Publicado: (2023)

Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
por: Tipaldi, Marcello Andrea, et al.
Publicado: (2021)

Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis
por: Yao, Man, et al.
Publicado: (2022)

Treatment of aortic thrombosis with retrievable stent filter and thrombolysis: a case report
por: Bi, Yonghua, et al.
Publicado: (2019)

Fluoroscopic Removal of Embedded Esophageal Self-Expanding Metal Stents: Stent-in-Stent Combined with Guidewire Lasso Technique
por: Bi, Yonghua, et al.
Publicado: (2021)

Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
por: Zhao, Shoujie, et al.
Publicado: (2020)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
por: Wu, Ying, et al.
Publicado: (2020)

HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Junguo, et al.
Publicado: (2022)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
por: Xiang, Zhanwang, et al.
Publicado: (2023)

Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin
por: Cui, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nm3ufjj55voe1u8a0tmd098amt